Financial Data and Key Metrics Changes - Net sales for Q4 2025 increased by 13.7% to $115.6 million from $101.6 million in Q4 2024, driven by $8.2 million in volume growth and a $6.3 million favorable impact from pricing and product mix [8][12] - Gross profit for Q4 2025 was $39.3 million, compared to $39.8 million in the prior year quarter, with a gross margin of 34.0%, down from 39.2% [10][12] - Net income for Q4 2025 rose by 22.8% to $7.2 million, with a net income margin of 6.2%, up from 5.8% in the prior year quarter [12] Business Line Data and Key Metrics Changes - Sales to chain accounts and distributors, the largest sales channel, increased by 17.5% in Q4 2025, while online sales rose by 1.9% and retail channel sales declined by 4.8% [8] - The new paper bag product category is gaining momentum, contributing to revenue growth and expanding market share [5][6] - Eco-friendly product sales grew to 37.3% of total revenue in Q4 2025, up from 34.5% in Q4 2024 [6] Market Data and Key Metrics Changes - The import mix during Q4 2025 consisted of 46% from Taiwan, 14% from China, 13% from the United States, and 11% each from Vietnam and Malaysia [4] - The California market is experiencing a slowdown, with overall restaurant closures impacting competition, although the company has seen double-digit growth due to tariff containment [48] Company Strategy and Development Direction - The company is focused on diversifying sourcing and optimizing margins, with expectations of margin improvements beginning in Q2 2026 due to favorable tariff developments [5][16] - Continued expansion in the paper bag category and the addition of new customer accounts are key strategies for driving top-line growth [17] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing trade volatility but emphasized the company's ability to deliver profitable growth [4] - For Q1 2026, the company expects net sales to increase by approximately 8%-10%, with gross margin anticipated to be within 34%-36% [16] - Management is optimistic about achieving low double-digit growth for the full year 2026, driven by market share gains and new product offerings [20][26] Other Important Information - The company generated operating cash flow of $15.4 million and free cash flow of $14.6 million in Q4 2025, despite high duties and tariff payments [13] - A regular quarterly dividend of $0.45 per share was approved, with $12.0 million remaining available for share repurchase [14][15] Q&A Session Summary Question: Outlook for 2026 and market assumptions - Management anticipates low double-digit growth, primarily from market share gains in new product categories, despite a competitive environment [20] Question: Q1 revenue slowdown and weather impact - Weather-related shutdowns in Texas and the East Coast affected Q1 performance, but trends are improving as conditions stabilize [22] Question: Full year revenue guidance and business opportunities - Revenue guidance includes potential new accounts in the final confirmation stages, but management remains conservative due to testing phases [26] Question: Margin outlook and energy costs - Energy costs are accounted for in margin guidance, with expectations of a 10%-15% year-over-year increase in ocean freight shipping costs [36] Question: Online sales growth and future platforms - Management expects double-digit growth in online sales for 2026, driven by the addition of new platforms and bulk sales strategies [40] Question: Demand for eco-friendly products and California market conditions - Demand for eco-friendly products remains strong, particularly for molded fiber and paper bags, while the California market is competitive with some restaurant closures [48]

Financial Data and Key Metrics Changes - The company reported approximately $690,000 in revenue from continuing operations for fiscal year 2025, entirely generated from the TrueCut Motion platform and related motion grading services [14] - The cash balance at the end of 2025 was approximately $11.2 million, which increased to approximately $62 million after the sale of the Shanghai subsidiary [4][15] - The company expects cash operating expenses to be approximately $2 million per quarter starting in the second quarter of 2026 [17] Business Line Data and Key Metrics Changes - The sale of the Shanghai semiconductor subsidiary allowed the company to reposition itself as a global technology licensing business focused on cinematic visualization solutions [5][6] - The company has transformed into a lean, asset-light organization with less than 25 full-time employees, 60% of whom are dedicated to R&D [7] Market Data and Key Metrics Changes - The company is focusing on expanding its TrueCut Motion platform, which is being utilized by leading filmmakers for premium theatrical releases [8][10] - There is a growing number of premium large format (PLF) screens, with major exhibitors investing in expanding premium theatrical experiences, which aligns with the company's strategy [9] Company Strategy and Development Direction - The company aims to enhance its core strengths in visualization enhancement solutions and pursue new licensing initiatives [6] - The immediate strategic focus is on enabling additional premium large format theatrical experiences and increasing demand for TrueCut Motion grading services [11] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of maintaining a robust balance sheet and managing resources prudently to build a profitable licensing business [12] - The company is optimistic about the market opportunity for its motion grading technology and expertise, particularly in the premium theatrical segment [10] Other Important Information - The company has approximately $1.2 million in escrow related to a tax dispute that is expected to be resolved in its favor [5] - The company has no intention of selling more patents and is focused on adding to its patent portfolio specific to its go-forward business [35] Q&A Session Summary Question: What are the best near-term opportunities for revenue? - Management highlighted the focus on engaging with studios and distributors to deliver premium experiences and the potential for revenue from home entertainment devices [20][24] Question: What is the margin structure as revenue forms? - Management indicated that gross margins are expected to be very high across various revenue streams, including content creation and licensing [26] Question: What are the top priorities for 2026? - The primary priorities include licensing the TrueCut Motion technology to third parties and developing demand for the product [37]

EverCommerce (NasdaqGS:EVCM) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Speaker8As a reminder, this conference call is being recorded today, March twelfth, two thousand and twenty-six. I would now like to turn the conference over to Brad Korch, SVP Finance and Head of Investor Relations for EverCommerce. Please go ahead.Speaker3Good afternoon, and thank you for joining. Today's call will be led by Eric Remer, EverCommerce's Chairman and Chief Executive Officer, and Ryan Siurek, EverCommerce's Chief Fi ...

Financial Data and Key Metrics Changes - Total net revenues for Q1 FY2026 were $18.2 million, down from $34.3 million in Q1 FY2025, reflecting a strategic transition to Sunkist and exiting brokerage operations [15][16] - Agribusiness revenues decreased to $16.8 million from $32.9 million year-over-year [15] - Adjusted net loss was $8.5 million or $0.48 per diluted share, compared to an adjusted net loss of $2.5 million or $0.14 per diluted share in the prior year [20][21] - Operating loss for Q1 FY2026 was $10.6 million, compared to a loss of $5.3 million in the prior year [19] Business Line Data and Key Metrics Changes - Fresh packed lemon sales were $11.9 million, down from $21.2 million in the same period last year, with a decrease in volume sold from 1,147,000 cartons to 681,000 cartons [16][17] - No avocado revenue was recorded in Q1 FY2026, compared to $162,000 in the prior year due to harvest timing [17] - Orange revenue fell to $10,000 from $1.6 million, reflecting the sale of Chilean agricultural properties [17] Market Data and Key Metrics Changes - The average price for lemons in Q1 FY2026 was $17.41 per carton, down from $18.44 in the prior year, with prices softening to around $16 in February [40][42] - Avocado pricing is under pressure due to a large crop from Mexico, with current prices around $1.00 per pound for size 48 avocados [40] Company Strategy and Development Direction - The company is focused on a strategic transformation to create sustainable long-term value, including a partnership with Sunkist to enhance customer access and reduce pricing pressure [5][7] - Cost structure improvements are expected to generate $10 million in selling, general, and administrative savings for FY2026 [23] - Expansion of avocado production is underway, with 1,600 acres planted and an expected near 100% increase in production capacity over the next 2-4 years [8] Management's Comments on Operating Environment and Future Outlook - Management anticipates sequential improvement in financial results throughout FY2026, with the second quarter expected to show better performance than the first [11][24] - The company is optimistic about the avocado crop due to favorable weather conditions, which are expected to support strong growth in FY2027 [33][34] - The strategic initiatives are believed to position the company for improved profitability as revenue cadence normalizes in the second half of the year [23][24] Other Important Information - The company is advancing the monetization of non-strategic assets and water rights, with a focus on maximizing value from its water resources [10][48] - The real estate development project, Harvest at Limoneira, is expected to generate $155 million in proceeds over the next five fiscal years [9] Q&A Session Summary Question: On the $10 million in expected SG&A savings, how much will be visible in the first half versus the back half? - Management indicated that the savings will not be linear and will show more significant reductions in the latter half of the year [29][30] Question: Update on avocado weather conditions? - Management reported ideal weather conditions in California, with good rain and temperatures expected to accelerate fruit growth [33][34] Question: Impact of fruit pricing and weather on lemons? - Management noted that lemon pricing has softened due to market supply but expects it to improve as the season progresses [42][43] Question: Opportunities for monetization of water assets? - Management highlighted ongoing negotiations regarding Colorado River water rights and the potential for monetization in the near term [48][49]

Financial Data and Key Metrics Changes - For Q4, net sales were $273 million, up 9% compared to Q3, exceeding expectations [26] - Gross margin was at 41%, slightly higher than guidance, maintaining above 40% for seven of the last eight quarters [26] - SG&A expenses decreased by 12% year-over-year to $91 million [26] - Adjusted EBITDA for Q4 was $23 million, at the high end of expectations [26] Business Line Data and Key Metrics Changes - Funko core product lines are expected to grow high single digits year-over-year in 2026, while Loungefly is projected to decline by double digits due to SKU cuts [28][29] - The Bitty Pop! product line has shown strong growth, contributing positively to sales [31] Market Data and Key Metrics Changes - In the EU, sales increased by 20% from January 2025 to January 2026, outperforming market growth [22] - The company is the second largest collectible brand by market share in Europe, following Pokémon [22] Company Strategy and Development Direction - The "Make Culture Pop!" strategy focuses on participating in cultural moments and expanding into new markets, particularly in Asia and Latin America [10][24] - A new Chief International Officer has been appointed to drive growth in Asia and Latin America, targeting significant opportunities in these regions [24] - The company aims to leverage its relationships with licensors and creators to tap into emerging cultural trends, especially from Asia [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing a strong entertainment slate and growth in collectibles, licensed IP, and the kidult market as key drivers [32][33] - The company expects net sales to be flat to up 3% in 2026, with a substantial improvement in profitability anticipated [28][30] Other Important Information - The company has renewed licenses with major studios, ensuring a strong position for the upcoming film slate [45] - The introduction of a new program called HyperStrike aims to enhance speed in product development and capitalize on viral trends [16][20] Q&A Session Summary Question: Describe the shape of the flat to +3% guidance past Q1 - The guidance is expected to be consistent throughout the year, with Q2 anticipated to show growth over last year [34] Question: To what extent does Funko view original content creation as a growth driver? - Original content creation is seen as a long-term growth driver, with plans to partner with major studios for development [35] Question: Does Funko need to use any of its extended credit agreement in 2026? - The company does not expect to need additional borrowing and plans to manage operations on cash flows [38] Question: Can you break out the POS trends and inventory restocking domestically versus Europe? - Double-digit growth in POS sales was observed in Europe, while the US saw improving trends throughout Q4 [39] Question: What would you highlight as the key initiatives to drive top line results and margin versus 2025? - Key initiatives include leveraging the content slate, expanding international growth, and launching new products [40]

Nephros (NasdaqCM:NEPH) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsAnthony Vendetti - Executive Managing Director of ResearchJudy Krandel - CFOKirin Smith - PresidentRobert Banks - President and CEOConference Call ParticipantsNone - AnalystOperatorGood afternoon, everyone, and welcome to the Nephros, Inc. fourth quarter 2025 financial results conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressin ...

Financial Data and Key Metrics Changes - INOVIO reported a net income of $3.8 million for Q4 2025, translating to $0.06 per share, while the total net loss for the full year was $84.9 million or $1.81 per share [25][26] - Total operating expenses decreased from $20.5 million in Q4 2024 to $17.5 million in Q4 2025, and full-year operational expenses dropped 23% from $112.6 million in 2024 to $86.9 million in 2025 [25][26] - Cash equivalents and short-term investments at the end of Q4 2025 were $58.5 million, down from $94.1 million as of December 31, 2024 [25] Business Line Data and Key Metrics Changes - The primary focus remains on advancing INO-3107 towards FDA approval, with significant resources allocated to this lead candidate [5][24] - INOVIO is also advancing other promising candidates in its pipeline, including INO-5412 for glioblastoma, through partnerships [8][22] Market Data and Key Metrics Changes - The market for recurrent respiratory papillomatosis (RRP) treatment is characterized by a significant burden on patients, with surgery being the standard of care [15] - Market research indicates that INO-3107 has the potential to become the preferred treatment option based on its efficacy and tolerability [16][18] Company Strategy and Development Direction - INOVIO's strategy includes optimizing resources to extend cash runway towards the October 30, 2026 PDUFA date for INO-3107 [24][60] - The company is leveraging partnerships to advance its pipeline and is focused on innovative treatments for rare diseases with significant unmet needs [22][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in INO-3107's ability to meet an unmet medical need and provide a meaningful therapeutic benefit over existing treatments [5][11] - The company is preparing for a meeting with the FDA to discuss the Accelerated Approval Program and has submitted additional documentation to support its case [10][30] Other Important Information - INOVIO has reduced its workforce by approximately 15% to conserve financial resources [24] - The company is actively preparing for the commercial launch of INO-3107, including selecting key commercial partners and finalizing its go-to-market model [19][24] Q&A Session Summary Question: What additional data is needed for the FDA regarding Accelerated Approval? - Management indicated that no new clinical data is required, but they have submitted an Assessment Aid to reiterate their rationale for Accelerated Approval [29][30] Question: How would a six-month priority review timeline impact launch preparations? - Management stated that they are focused on ensuring alignment with the FDA for Accelerated Approval and are well advanced in commercial preparations [33][34] Question: How are third-party logistics and commercial partners being used to inform distribution strategy? - Management noted that they are learning from competitors and leveraging the experience of their partners to ensure a well-prepared launch [42][43] Question: Can you explain the rationale behind the Akeso partnership for GBM? - Management explained that combining PD-1 and CTLA-4 blockade is expected to enhance immune responses against tumor-associated antigens [48][49] Question: What are the plans for moving forward with 3112 if INO-3107 is approved? - Management indicated that resources are currently focused on INO-3107, but if approved, they will consider advancing 3112 based on available financial resources [55]

Heartbeam (NasdaqCM:BEAT) Q4 2025 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsBryan Humbarger - CCORobert Eno - Founder and Executive ChairmanTimothy Cruickshank - CFONone - Company RepresentativeConference Call ParticipantsBill Sutherland - Equity Research AnalystKyle Bauser - Equity Research AnalystLeo Carpio - Equity Research AnalystNone - AnalystOperatorGreetings, and welcome to the HeartBeam fourth quarter 2025 financial results conference call. At this time, all participants are in a ...

Financial Data and Key Metrics Changes - Total revenue for the quarter was $16.6 million, a decrease of approximately 3% compared to $17 million in the prior year period [11] - Core study revenue reached a record $16.6 million, representing growth of approximately 32% from $12.6 million in the year-ago period [11] - Adjusted EBITDA for the quarter was $575,000, marking the third consecutive quarter of positive adjusted EBITDA [13] - GAAP loss from operations for the quarter was approximately $275,000 [13] - Gross margin for the quarter was 47%, down from 61% in the prior year period [13] Business Line Data and Key Metrics Changes - The core translational oncology services platform demonstrated strong performance, with record services revenue driven by effective study execution and conversion of previously booked work [3][11] - Data revenue was not recognized in the third quarter, compared to $4.5 million in the prior year period, contributing to the overall year-over-year revenue decline [12] - The company anticipates that data revenue will become a more meaningful contributor over time as the platform develops [12] Market Data and Key Metrics Changes - The company noted that customer budgets are stabilizing, leading to improved bookings converting into revenue [3] - There is a healthy underlying demand for the company's services, with expectations for revenue normalization as studies progress [4] Company Strategy and Development Direction - The company is focused on balancing growth and investment while maintaining positive adjusted EBITDA [5] - Investments are being made in both the data platform and the therapeutic subsidiary, Corellia, without diluting shares [5][9] - The company aims to maximize shareholder value across its differentiated tumor bank, radiopharmaceutical capabilities, and therapeutic subsidiary [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year revenue growth and positive adjusted EBITDA while continuing to invest in growth drivers [5][10] - The company expects to see the payoff from current investments beginning in fiscal 2027, with more meaningful acceleration anticipated in fiscal 2028 [5][10] - Discussions regarding external funding for Corellia are ongoing, with positive feedback from potential partners [8][9] Other Important Information - The company ended the quarter with $7.1 million in cash and no debt, maintaining a cash balance within projected ranges [16] - Operating expenses increased to $7.2 million, reflecting strategic investments in R&D, sales, and marketing [15] Q&A Session Summary - There were no questions from participants during the Q&A session [17]

Limoneira Company (NasdaqGS:LMNR) Q1 2026 Earnings call March 12, 2026 04:30 PM ET Company ParticipantsAdam Shepherd - Equity Research AssociateGreg Hamm - CFOHarold Edwards - President and CEOJohn Mills - Managing PartnerConference Call ParticipantsMark Smith - Senior Research AnalystOperatorGood evening, and welcome to Limoneira's first quarter 2026 financial results conference call. At this time, all participants are on a listen-only mode. A brief question-and-answer session will follow the formal presen ...